started · updated
Biomatter raises $18 million for AI-driven enzyme design
Biomatter, a company specializing in custom enzyme design, has secured $18 million in an oversubscribed Series A funding round. The financing was led by Astanor, with participation from existing investors UVC Partners, Inventure, and Metaplanet.
The company utilizes computational models and a proprietary dataset of experimentally characterized enzymes to design custom enzymes tailored to specific chemical reactions. This approach aims to reduce development timelines from months or years to just weeks or days. Biomatter’s technology is applied across the pharmaceutical, diagnostic, agricultural, and industrial biotechnology sectors.
Biomatter has already delivered over 50 enzymes to more than 25 enterprise customers across Europe, the United States, and Japan, including AstraZeneca, BASF, Sanofi, and Tereos. The company also collaborated with Thermo Fisher Scientific to improve enzyme stability for molecular biology and mRNA research.
The new capital will be used to expand the company’s commercial team, computational platform, and U.S. operations. Additionally, Biomatter plans to open a 2,000-square-meter design and testing facility in Vilnius, scheduled for 2027, to bring more testing in-house.
Entities
Astanor · AstraZeneca · Biomatter · Laurynas Karpus · Thermo Fisher Scientific